COPD lung studies of Nrf2 expression and the effects of Nrf2 activators.

Jian LiJames BakerAndrew HighamRajesh ShahAngeles Montero-FernandezClare MurrayNicky CooperCathy LucasCraig FoxDave SinghSimon Lea

Published in: Inflammopharmacology (2022)

There is evidence of dysregulation of the Nrf2 signalling pathway in AM from COPD patients. The higher potency of the novel PPI Nrf2 compound C4X_6665 for inducing antioxidant activity and gene expression compared to electrophilic and other PPI Nrf2 activators highlights the therapeutic potential of this compound to address Nrf2 pathway dysregulation in COPD AM.

Keyphrases

oxidative stress
chronic obstructive pulmonary disease
gene expression
lung function
end stage renal disease
newly diagnosed
poor prognosis
chronic kidney disease
protein protein
peritoneal dialysis
small molecule
cystic fibrosis
long non coding rna
patient reported